Inovio Pharmaceuticals Inc

Type: Company
Name: Inovio Pharmaceuticals Inc
First reported Jul 29 2014 - Updated Jul 29 2014 - 1 reports

US securities lending revenues see rebound

Equity balances are up by 20% year to date which, along with an increased demand for specials, has seen the aggregate revenues rise by over 3% ETFs and ADRs saw large surges in revenue Fixed income driving much of the increased revenue as the asset ... [Published Markit - Jul 29 2014]
First reported Jul 24 2014 - Updated Jul 25 2014 - 1 reports

3 Game-Changing Stories That Shook Investors: Inovio Pharmaceuticals, Gilead Sciences, and GlaxoSmit

The health care sector exploded with major news events yesterday, fueled by second-quarter earnings, clinical trial updates, and even unexpected regulatory events.Given that the day's headlines seemed to be dominated by Puma Biotechnology's stunning 295% ... [Published Motley Fool - Jul 24 2014]
First reported Jul 25 2014 - Updated Jul 25 2014 - 1 reports

Cramer's Lightning Round - What's Up With Tupperware? (7/24/14)

Jul. 25, 2014 5:54 AM ET | Includes: AAPL, BIDU, CLNE, FB, GOOG, GOOGL, IBM, INO, JD, KNDI, TUP, UTX by: SA Editor Miriam MetzingerStocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday July 24.Bullish Calls:Inovio ... [Published Seeking Alpha - Jul 25 2014]
First reported Jul 24 2014 - Updated Jul 25 2014 - 2 reports

Inovio Pharmaceuticals Short Interest Up 21.8% in July (INO)

Shares of Inovio Pharmaceuticals (NYSE:INO) saw a significant increase in short interest during the month of July. As of July 15th, there was short interest totalling 11,982,183 shares, an increase of 21.8% from the June 30th total of 9,833,973 shares, ... [Published American Banking News - Jul 25 2014]
First reported Jul 24 2014 - Updated Jul 25 2014 - 2 reports

Ho-Hum, Another Boring Day of Little Volume in the Markets

NEW YORK ( TheStreet ) -- Another boring trading day in the stock market on Thursday. The S&P 500 Trust Series ETF volume did not even trade 60 million shares. The volume came in at 56 million shares.After being up for most of the day, the DJIA closed ... [Published Joshua Star - Jul 24 2014]
First reported Jul 24 2014 - Updated Jul 24 2014 - 1 reports

Inovio Pharma's Immunotherapy for Cervical Dysplasia Meets Goal

Reuters Health InformationBy Reuters StaffJuly 24, 2014(Reuters) - Inovio Pharmaceuticals Inc announced positive results from its randomized, double-blind, placebo-controlled phase II trial of VGX-3100 in women with biopsy-proven cervical intraepithelial ... [Published General Medicine eJournal - Jul 24 2014]
First reported Jul 24 2014 - Updated Jul 24 2014 - 2 reports

Here Are 4 Momentum Charts to Watch for Thursday Trading

07/24/14 - 01:54 PM EDTNEW YORK ( TheStreet ) -- Here are four stocks in strong uptrends, at or near key breakout levels with more room to run.Inovio Pharmaceuticals ( INO ) has had quite a pop in the last four days, going from $9.40 all the way up to ... [Published TheStreet.com - Jul 24 2014]
First reported Jul 24 2014 - Updated Jul 24 2014 - 1 reports

This Says Our Favorite Biotech Is Off to the Races

Shares of Inovio Pharmaceuticals Inc. (NYSE: INO) - a promising biotech we recommended back in February 2013 - jumped as much as 27% to a three-month high of $14.20 yesterday after the company said a new cancer drug met its main goal in a midstage ... [Published Money Morning - Jul 24 2014]
First reported Jul 24 2014 - Updated Jul 24 2014 - 1 reports

Healthcare Review: Biogen Idec, Inovio Pharmaceuticals, Intuitive Surgical, Puma Biotechnology, Gilead Sciences

:28 U.S. stock indexes were mostly higher in early-afternoon trading Wednesday as investors weighed positive earnings from the technology industry against disappointing news from Boeing and other companies.Biotechnology stocks were among the biggest ... [Published BioMedReports - Jul 24 2014]
First reported Jul 23 2014 - Updated Jul 23 2014 - 5 reports

Inovio's HPV Immunotherapy Hits Primary Endpoint

Inovio Pharmaceuticals Inc. announced successful results from its randomized, double-blind, placebo-controlled Phase 2 trial of VGX-3100 in women with biopsy-proven cervical intraepithelial neoplasia 2/3 (CIN2/3) associated with human papillomavirus (HPV) ... [Published Drug Discovery and Development - Jul 23 2014]
First reported Jul 10 2014 - Updated Jul 11 2014 - 2 reports

Inovio Pharmaceuticals Short Interest Down 24.7% in June (INO)

Shares of Inovio Pharmaceuticals (NYSE:INO) were the recipient of a large drop in short interest during the month of June. As of June 30th, there was short interest totalling 9,833,973 shares, a drop of 24.7% from the June 13th total of 13,067,325 shares, ... [Published American Banking News - Jul 11 2014]
First reported Jul 01 2014 - Updated Jul 01 2014 - 3 reports

Inovio Pharmaceuticals Added To Russell Global, Russell 2000® and Russell Microcap® Indexes

SOURCE Inovio Pharmaceuticals, Inc.Inovio Shares Enter No. 1 U.S. Equity Index for Asset BenchmarkingPLYMOUTH MEETING, Pa. , July 1, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced that it has been added to the Russell Global, ... [Published KSFY - Jul 01 2014]

Quotes

"Velop45" asks: "Adam, I appreciate you keeping us on top of biotech events but I was hoping to hear more from you about Intercept Pharmaceuticals"
Inovio Pharmaceuticals (NYSEMKT:INO): "It has irons on the fire. This is the kind of company Janet Yellen doesn't like, but I like it on a speculative basis."
"This proof of concept trial will guide the advancement of VGX-3100 for precancerous dysplasias as well as HPV-associated cervical, head and neck, and anogenital cancers" he added
...J Joseph Kim, Inovio's president and CEO. "These results significantly de-risk our product and business development strategy for VGX-3100 and our broad pipeline of SynCon® active immune therapy and vaccine products."

More Content

All (136) | News (101) | Reports (0) | Blogs (24) | Audio/Video (0) | Fact Sheets (0) | Press Releases (11)
sort by: Date | Relevance
US securities lending revenues see rebound [Published Markit - Jul 29 2014]
Mannkind Corporation (MNKD) Sinks As Biotech Ha... [Published Value Walk - Jul 28 2014]
Biotech Stock Mailbag: Intercept Pharma, Inovio [Published TheStreet.com - Jul 25 2014]
Biotech Stock Mailbag: Intercept Pharma, Inovio [Published The Street Latest - Jul 25 2014]
Cramer's Lightning Round - What's Up With Tuppe... [Published Seeking Alpha - Jul 25 2014]
Inovio Pharmaceuticals Short Interest Up 21.8% ... [Published American Banking News - Jul 25 2014]
Ho-Hum, Another Boring Day of Little Volume in ... [Published Joshua Star - Jul 24 2014]
Inovio Pharma's Immunotherapy for Cervical Dysp... [Published General Medicine eJournal - Jul 24 2014]
Ho-Hum, Another Boring Day of Little Volume in ... [Published The Street Latest - Jul 24 2014]
Top Analysts Action: INO, TXN, FB, PSXP, PEP [Published BayStreet.ca - Jul 24 2014]
Here Are 4 Momentum Charts to Watch for Thursda... [Published TheStreet.com - Jul 24 2014]
3 Game-Changing Stories That Shook Investors: I... [Published Motley Fool - Jul 24 2014]
Here Are 4 Momentum Charts to Watch for Thursda... [Published The Street Latest - Jul 24 2014]
Research Analysts’ Upgrades for July, 24th (CIB... [Published American Banking News - Jul 24 2014]
Inovio Pharmaceuticals Rating Increased to Buy ... [Published American Banking News - Jul 24 2014]
This Says Our Favorite Biotech Is Off to the Races [Published Money Morning - Jul 24 2014]
Healthcare Review: Biogen Idec, Inovio Pharmace... [Published BioMedReports - Jul 24 2014]
Is Inovio Undervalued After Positive HPV Therap... [Published BioPortfolio - Jul 24 2014]
Mixed Session, Getting a Little Long in the Tooth [Published Individual.com - Jul 23 2014]
Doral Financial Corp. (DRL) is Top Small-Cap St... [Published Equities.com - Jul 23 2014]
Leading Health Care Stock for Small-Cap Stars i... [Published Equities.com - Jul 23 2014]
The S&P 500 Closes at Yet Another All-Time Clos... [Published The Street Latest - Jul 23 2014]
Inovio's HPV Immunotherapy Hits Primary Endpoint [Published Drug Discovery and Development - Jul 23 2014]
S&P Secures Another New High; Dow Jones Industr... [Published Schaeffers Research - Jul 23 2014]
Is Inovio Undervalued After Positive HPV Therap... [Published Seeking Alpha - Jul 23 2014]
Inovio shares jump on positive data from pre-ca... [Published MedCity News - Jul 23 2014]
Doral Financial Corp. (DRL) Leading Small-Cap S... [Published Equities.com - Jul 23 2014]
Hottest Healthcare Stocks Now – PBYI INO ISRG BIIB [Published InvestorPlace.com - Jul 23 2014]
Inovio vs. Feuerstein, Round II: Biotech claims... [Published FierceBiotech - Jul 23 2014]
BUZZ-U.S. Stocks on the Move-Apple, Microsoft, ... [Published London South East - Jul 23 2014]
1 2 3 4 5
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Inovio Pharmaceuticals HPV Immunotherapy Achiev... [Published PR Newswire: Health - Jul 23 2014]
PLYMOUTH MEETING, Pa., July 23, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced successful results from its randomized, double-blind, placebo-controlled phase II trial of VGX-3100 in women with biopsy-proven cervical ...
Inovio begins Phase I/IIa cervical cancer trial... [Published PBR - News - Jun 24 2014]
US-based Inovio Pharmaceuticals has started a Phase I/IIa clinical trial of its DNA immunotherapy product, INO-3112, for the treatment of human papillomavirus (HPV)-associated cervical cancer. ...
Inovio Pharmaceuticals Initiates Cervical Cance... [Published PR Newswire: Health - Jun 23 2014]
BLUE BELL, Pa., June 23, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced it has initiated a phase I/IIa clinical trial to evaluate safety, immunogenicity, clinical responses and disease-free survival of its DNA immunotherapy ...
Inovio Pharmaceuticals Broadens its Intellectua... [Published PR Newswire: General Business - Jun 17 2014]
BLUE BELL, Pa., June 17, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) has expanded its existing license agreement with the University of Pennsylvania, adding exclusive worldwide rights to technology and intellectual property for ...
Inovio Pharmaceuticals to Present at Upcoming H... [Published PR Newswire: General Business - Jun 16 2014]
BLUE BELL, Pa., June 16, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that President & CEO, Dr. J. Joseph Kim, will participate in a panel at the Piper Jaffray GenomeRx Symposium on June 23 to discuss Inovio's ...
1 2 3 4 5

Press Releases

sort by: Date | Relevance
Biotech Stocks Highlight -- Research on Celgene... [Published Financial Services - Jul 09 2014]
Inovio Pharmaceuticals Added To Russell Global,... [Published Financial Services - Jul 01 2014]
Biotechnology Equities Technical Notes -- Resea... [Published Financial Services - Jun 26 2014]
Inovio Pharmaceuticals Announces 1 For 4 Revers... [Published Financial Services - May 23 2014]
Inovio Pharmaceuticals Reports 2014 First Quart... [Published Financial Services - May 12 2014]
1 2 3
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.